Two Months To Add Two Words – Biosimilar Supplement Review Times May Be Hindering Uptake
Executive Summary
Biosimilar supplement approvals by the US FDA take on average about five months as sponsors request easier and quicker ways to update labels.
You may also be interested in...
US FDA’s Biosimilars Group Will Conduct Some Supplement Reviews, Become ‘Like Another Discipline’
Office of Therapeutic Biologics and Biosimilars Director Sarah Yim says in an interview with the Pink Sheet that more staff are being added to deal with labeling supplements.
US FDA’s Biosimilars Group Will Conduct Some Supplement Reviews, Become ‘Like Another Discipline’
Office of Therapeutic Biologics and Biosimilars Director Sarah Yim says in an interview with the Pink Sheet that more staff are being added to deal with labeling supplements.
FDA Publishes BsUFA III Commitment Letter Ahead Of 2022 Renewal
Following months of negotiations with industry and stakeholders, the FDA has released the commitment letter for the third iteration of its five-year Biosimilar User Fee Amendments program, marking another step ahead of its reauthorization.